TY - JOUR
AU - Godolphin, Peter J.
AU - Fisher, David J.
AU - Berry, Lindsay R.
AU - Derde, Lennie
AU - Diaz, Janet V.
AU - Gordon, Anthony C.
AU - Lorenzi, Elizabeth
AU - Marshall, John C.
AU - Murthy, Srinivas
AU - Shankar-Hari, Manu
AU - Sterne, Jonathan A. C.
AU - Tierney, Jayne F.
AU - Vale, Claire L.
PY - 2022
DA - July
TI - Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis
JO - PLoS ONE
VL - 17
IS - 7
DO - https://doi.org/10.1371/journal.pone.0270668
AB - Background:A recent prospective meta-analysis demonstrated that interleukin-6 antagonists are associated with lower all-cause mortality in hospitalised patients with COVID-19, compared with usual care or placebo. However, emerging evidence suggests that clinicians are favouring the use of tocilizumab over sarilumab. A new randomised comparison of these agents from the REMAP-CAP trial shows similar effects on in-hospital mortality. Therefore, we initiated a network meta-analysis, to estimate pairwise associations between tocilizumab, sarilumab and usual care or placebo with 28-day mortality, in COVID-19 patients receiving concomitant corticosteroids and ventilation, based on all available direct and indirect evidence.
PB - Public Library of Science
UR - https://www.research.ed.ac.uk/en/publications/cb7589e8-1fdd-4c69-b5a7-d7437a7cc71b
KW - Coronavirus (COVID-19)
ER